Cerebellum GP LLC bought a new stake in shares of Metlife Inc (NYSE:MET) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 11,351 shares of the financial services provider’s stock, valued at approximately $579,000. Metlife comprises about 0.3% of Cerebellum GP LLC’s investment portfolio, making the stock its 7th largest holding.
A number of other institutional investors have also recently made changes to their positions in the business. United Capital Financial Advisers LLC raised its position in shares of Metlife by 11.2% in the second quarter. United Capital Financial Advisers LLC now owns 36,421 shares of the financial services provider’s stock valued at $1,809,000 after buying an additional 3,658 shares in the last quarter. Evercore Wealth Management LLC raised its position in shares of Metlife by 17.3% in the second quarter. Evercore Wealth Management LLC now owns 6,137 shares of the financial services provider’s stock valued at $304,000 after buying an additional 906 shares in the last quarter. Johnson Investment Counsel Inc. raised its position in shares of Metlife by 16.6% in the second quarter. Johnson Investment Counsel Inc. now owns 20,947 shares of the financial services provider’s stock valued at $1,040,000 after buying an additional 2,975 shares in the last quarter. Sterling Capital Management LLC raised its position in shares of Metlife by 81.0% in the second quarter. Sterling Capital Management LLC now owns 180,999 shares of the financial services provider’s stock valued at $8,990,000 after buying an additional 80,990 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Metlife by 1.2% in the second quarter. Vanguard Group Inc. now owns 67,442,713 shares of the financial services provider’s stock valued at $3,349,879,000 after buying an additional 797,115 shares in the last quarter. 74.46% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have recently weighed in on the stock. Morgan Stanley upgraded shares of Metlife from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $55.00 to $60.00 in a research report on Tuesday, January 7th. Wells Fargo & Co reissued a “buy” rating on shares of Metlife in a research note on Monday, January 6th. B. Riley reissued a “neutral” rating on shares of Metlife in a research note on Tuesday, October 15th. UBS Group lifted their price objective on shares of Metlife from $46.00 to $47.00 and gave the company a “neutral” rating in a research note on Thursday, October 10th. Finally, ValuEngine raised shares of Metlife from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 21st. Two analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $50.34.
Shares of NYSE:MET opened at $51.85 on Thursday. The company’s 50 day simple moving average is $50.71 and its 200 day simple moving average is $48.33. The stock has a market capitalization of $48.00 billion, a price-to-earnings ratio of 9.62, a price-to-earnings-growth ratio of 1.00 and a beta of 1.13. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.15 and a quick ratio of 0.15. Metlife Inc has a 1 year low of $41.41 and a 1 year high of $52.76.
Metlife (NYSE:MET) last announced its quarterly earnings data on Wednesday, October 30th. The financial services provider reported $1.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.40 by ($0.13). The firm had revenue of $16.92 billion during the quarter, compared to the consensus estimate of $16.37 billion. Metlife had a net margin of 10.82% and a return on equity of 8.82%. The business’s revenue was up 3.2% compared to the same quarter last year. During the same period last year, the business earned $1.38 earnings per share. As a group, analysts anticipate that Metlife Inc will post 5.53 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 13th. Shareholders of record on Tuesday, February 4th will be paid a dividend of $0.44 per share. The ex-dividend date of this dividend is Monday, February 3rd. This represents a $1.76 dividend on an annualized basis and a dividend yield of 3.39%. Metlife’s payout ratio is presently 32.65%.
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Featured Story: What is a Derivative?
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.